Teses / dissertações sobre o tema "Matrix metalloproteinase 1 (MMP1)"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores trabalhos (teses / dissertações) para estudos sobre o assunto "Matrix metalloproteinase 1 (MMP1)".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja as teses / dissertações das mais diversas áreas científicas e compile uma bibliografia correta.
Kumar, Deepak. "Mechanism of induction of matrix metalloproteinase-1 (MMP-1) during osteoarthritis /". Free to MU Campus, others may purchase, 2004. http://wwwlib.umi.com/cr/mo/fullcit?p3144432.
Texto completo da fonteSroka, Isis Calsoyas. "Regulation Of Membrane-Type 1 Matrix Metalloproteinase In Prostate Cancer". Diss., The University of Arizona, 2007. http://hdl.handle.net/10150/194830.
Texto completo da fonteAnand, Monika. "FUNCTION AND REGULATION OF MATRIX METALLOPROTEINASE-1 IN GLIOBLASTOMA MULTIFORME". VCU Scholars Compass, 2010. http://scholarscompass.vcu.edu/etd/2214.
Texto completo da fonteMullet, Emily. "Functional Consequences of Matrix Metalloproteinase-1 Over-Expression in Human Gliomas". VCU Scholars Compass, 2006. http://hdl.handle.net/10156/1437.
Texto completo da fonteNguyen, Khanh Vu Thuy. "The Effects of Scaling and Root Planing on the Systemic Levels of Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1)". VCU Scholars Compass, 2007. http://scholarscompass.vcu.edu/etd_retro/160.
Texto completo da fonteArnold, Laurence. "Biophysical characterisation of collagen binding by the hemopexin domain of matrix metalloproteinase-1 (MMP-1)". Thesis, University of Portsmouth, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.516871.
Texto completo da fonteLi, He. "A study of fibroblast-mediated contraction in ocular scarring : gene expression profiling and the role of small GTPases in Matrix Metalloproteinase 1 (MMP1) regulation". Thesis, University College London (University of London), 2017. http://discovery.ucl.ac.uk/10024949/.
Texto completo da fonteSritharan, Kajanatharshni. "The role of membrane type-1 matrix metalloproteinase (MT1-MMP) in carotid plaque instability". Thesis, Imperial College London, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.517390.
Texto completo da fonteWang, Fang St George Clinical school UNSW. "Oxidative stress induced C-Jun N-terminal Kinase (JNK) activation in tendon cells upregulates MMP1 mRNA and protein expression". Awarded by:University of New South Wales. St George Clinical school, 2006. http://handle.unsw.edu.au/1959.4/28815.
Texto completo da fonteHarada, Tomika. "Membrane-type matrix metalloproteinase-1(MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas". Kyoto University, 1999. http://hdl.handle.net/2433/181703.
Texto completo da fonteZinzindohoue, Franck. "Influence de deux polymorphismes nucléotidiques fonctionnels des régions promotrices des gènes de MMP-1 (-1607ins/delG) et de MMP-3 (-1612ins/delA) au cours des cancers ORL et des cancers colorectaux". Paris 5, 2005. http://www.theses.fr/2005PA05S021.
Texto completo da fonteWe studied the influence of functional nucleotide polymorphisms in MMP-1 (-1607ins/delG) and MMP-3 (-1612ins/delA) gene promoters in cancer. In a case-control study on head and neck squamous cell carcinoma, we demonstrate that MMP-1 -1607delG homozygous patients had a greater risk of cancer. In a second study, we demonstrated the predictive value of MMP-3 polymorphysm on response to 5FU-CisPt neoadjuvante chemotherapy. In a third study on a colorectal cancer patient series, MMP-1 1607insG stages 2 and 3 homozygous patients (TNM classification) had a shorter survival. In conclusion, our results confirm that nucleotide polymorphisms in MMP-1 and MMP-3 gene promoters could play a role in the occurrence of cancer, in its prognosis, and could be a factor of predictive value of response to neoadjuvante chemotherapy
Vasala, K. (Kaija). "Matrix metalloproteinase MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 in bladder carcinoma". Doctoral thesis, University of Oulu, 2008. http://urn.fi/urn:isbn:9789514288746.
Texto completo da fonteKormi, I. (Immi). "Translational perspectives on matrix metalloproteinase 8 and other inflammatory biomarkers in cardiovascular diseases". Doctoral thesis, Oulun yliopisto, 2017. http://urn.fi/urn:isbn:9789526215297.
Texto completo da fonteTiivistelmä Sydän- ja verisuonisairaudet, erityisesti ateroskleroottiset valtimosairaudet, ovat maailman yleisin sairastuvuuden ja ennenaikaisen kuoleman syy. Sepelvaltimotauti ja aivohaveri ovat ateroskleroottisen valtimosairauden yleisiä ja vakavia ilmenemismuotoja. Ateroskleroosi on krooninen tulehduksellinen sairaus ja lipoproteiiniaineenvaihdunnan häiriö. Jos tulehdustapahtuma häiriintyy, elimistöön vapautuvat tulehdusvälittäjäaineet, kuten matriksin metalloproteinaasit (MMP), voivat aiheuttaa elimistön matala-asteisen tulehduksen, joka on sydän- ja verisuonisairauksien riskitekijä. MMP:t ovat entsyymejä, jotka pilkkovat solunväliainetta kasvun ja kudosten uusiutumisen mutta myös monien tautitilojen yhteydessä. Nämä soluväliainetta hajottavat proteaasit ja niiden säätelijät ovat tärkeässä roolissa ateroskleroottisen plakin muodostumisessa ja repeämisessä, joka johtaa äkillisiin sydäntautitapahtumiin. Matriksin metalloproteinaasien keskeinen rooli ateroskleroosissa on herättänyt kiinnostusta niihin kohdistuvan lääkehoidon kehittämiseen. Doksisykliinillä on joidenkin MMP-entsyymien toimintaa estävä vaikutus antimikrobiaalisten ominaisuuksiensa lisäksi. Tämän väitöskirjatutkimuksen päätavoitteena oli tutkia näiden tulehdusvälittäjäaineiden mahdollisuuksia biomarkkereina, riskitekijöinä ja lääkehoidon kohteena sydän- ja verisuonisairauksissa. Erityinen kiinnostuksen kohde oli MMP-8 ja sen pääsäätelijä ja kudosestäjä, tissue inhibitor of matrix metalloproteinase (TIMP)-1. Tämän tutkimuksen tulokset osoittavat, että seerumin korkea MMP 8 pitoisuus viittaa akuuttiin sydäntautiin ja ennakoi tulevaa sydäntautitapahtumaa. MMP-8:n lisäksi MMP-7 on lupaava sydäntapahtuman biomarkkeri. Näiden matriksin metalloproteinaasien ja niiden kudossäätelijä TIMP-1:n välinen tasapaino voi liittyä ateroskleroottisen plakin haurauteen. Seerumin MMP-8:n mittaus on luotettavaa, kajoamatonta ja edullista, ja mahdollista toteuttaa myös sairaalaolosuhteissa. Näytämme myös, että doksisykliini vähentää elimistön tulehdustaakkaa sydäninfarktin sairastaneilla potilailla ja että se on sydäntautien ehkäisyssä lupaava anti-inflammatorinen lääke, jolla on suhteellisen vähän sivuvaikutuksia. Johtopäätöksenä on, että MMP-8:aa ja TIMP-1:tä voidaan pitää lupaavina sydän- ja verisuonitautien sekä kuoleman biomarkkereina sekä diagnostiikka- että seulontakäytössä. Lisäksi tutkimustulokset osoittavat, että MMP-8:n esto doksisykliinillä voi vähentää elimistön tulehdustaakkaa sydänkohtauksen sairastaneilla potilailla
Farooqi, Owais Ali. "Effect of methamphetamine on gingival fibroblast production of matrix metalloproteinase (MMP)-2 and -9 and tissue inhibitor of metalloproteinase (TIMP)-1 and -2 in vitro". View the abstract Download the full-text PDF version, 2009. http://etd.utmem.edu/ABSTRACTS/2009-023-Farooqi-index.htm.
Texto completo da fonteTitle from title page screen (viewed on August 5, 2009). Research advisor: David A. Tipton, D.D.S., Ph.D. Document formatted into pages (vi, 39 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 27-38).
Bednarek, Nathalie. "Mmp-2, -9, timp-1, -2 : recherche de biomarqueurs de lésions cérébrales chez l'enfant prématuré et à terme". Paris 7, 2008. http://www.theses.fr/2008PA077103.
Texto completo da fonteThe perinal brain injuries are a major cause of death or handicap. We hypothezise that the MMP-2, -9, and the TIMP- 1 and 2 could be early markers of these cerebral lesions. The cortical profile of MMP-2, -9, TIMP-1 and -2 was studied during embryonic life to adulthood. The plasmatic neonatal profiles were studied according to the gestational age, gender and neonatal pathologies. They were also studied in animal models of perinatal brain injuries. MMP-2, TIMP-1 are largely expressed during embryonic life and TIMP-2 more likely in early post-natal period. MMP-9 is quasi undetectable whatever the moment. Gender does not influence the expression of MMP-2, -9 and their inhibitors in the new-born as well as in the mouse. In ischemic encephalopathy, MMP-9 and TIMP- 1 are specifically raised in new-born plasma but also in mice brain and plasma. In PWMD new-born, no gelatinase or inhibitor elevation was seen, but in mouse cortex and plasma, an exclusive and transitory raise of TIMP-1 is obvious. This preliminary study brings arguments to explore MMP-9 and TIMP-1 as severity and prognosis markers in hypoxic-ischemic encephalopathy
Honkavuori-Toivola, M. (Maria). "The prognostic role of matrix metalloproteinase-2 and -9 and their tissue inhibitor-1 and -2 in endometrial carcinoma". Doctoral thesis, Oulun yliopisto, 2014. http://urn.fi/urn:isbn:9789526204505.
Texto completo da fonteTiivistelmä Kohdunrungon syöpä on yleisin gynekologinen maligniteetti kehittyneissä maissa. Varhaisten oireiden, kuten poikkeavan verisen vuodon, vuoksi kohdunrungon syöpä havaitaan usein varhaisessa vaiheessa, jolloin sen ennuste on hyvä. Taudin käyttäytyminen voi kuitenkin olla moninaista. Viime vuosikymmenten aikana kohdunrungon syöpään sairastuneiden ennuste ei ole merkittävästi parantunut. Vaikuttaisi siltä, että perinteiset ennustetekijät eivät ole riittävän tarkkoja ennustamaan syövän taudinkulkua. Lisäksi liitännäishoidot voivat olla kalliita, ja niihin voi liittyä vakavia haittavaikutuksia. Uusien biologisten ennustetekijöiden löytäminen olisi tärkeää, jotta aggressiivista syöpätyyppiä sairastavat potilaat pystyttäisiin tunnistamaan entistä paremmin, ja hoito kyettäisiin räätälöimään yksilöllisemmin taudinkuvaa vastaavasti. Gelatinaasien (MMP-2 ja MMP-9) sekä niiden kudosinhibiittoreiden (TIMP-1 ja TIMP-2) on havaittu osallistuvan syövän etenemiseen. Tässä tutkimuksessa tarkasteltiin MMP-2:n ja MMP-9:n sekä niiden kudosinhibiittoreiden TIMP-1:n ja TIMP-2:n ilmentymistä ja ennusteellista merkitystä kohdunrungon syövässä. Aineisto käsitti yhteensä 266 primaariseen kohdunrungon syöpään sairastunutta naista. Määritysmenetelminä käytettiin sekä immunohistokemiallista värjäystä parafiiniin valettujen kudosnäytteiden osalta että ELISA-määrityksiä ennen hoitoa otettujen seeruminäytteiden osalta. Syöpäkudoksen runsas MMP-2 -proteiinin ilmentyminen liittyi epäsuotuisaan ennusteeseen, kun taas kasvainkudoksen voimakas TIMP-2 -proteiinin ilmentyminen oli hyvän ennusteen merkki. Lisäksi kasvainkudoksen voimakkaan MMP-2- ja heikon TIMP-2 -proteiinien ilmentymisen yhdistelmän havaittiin liittyvän suurempaan syövästä johtuvaan kuolleisuuteen. MMP-2 -negatiivisten potilaiden eloonjäämisennuste oli paras, TIMP-2 -värjäystuloksesta riippumatta. Seerumin korkea TIMP-1 -pitoisuus oli merkittävä huonontuneen ennusteen merkki. Tutkimuksen tulokset viittaavat siihen, että kasvainkudoksessa esiintyvät MMP-2- ja TIMP-2 -proteiinit samoin kuin seerumin TIMP-1 -pitoisuus voivat ennustaa kohdunrungon syövän kliinistä käyttäytymistä. Kasvainkudoksessa esiintyvä MMP-2 -proteiini vaikuttaisi olevan merkittävin ennusteellinen tekijä, mutta tulosten varmistamiseksi tarvitaan lisää tutkimuksia suuremmilla potilasaineistoilla
Westin, Maria Cristina do Amaral 1949. "Expressão das proteínas MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2 e VEGF-A na NIC 3 e no carcinoma invasor do colo do útero = Expression of the proteins MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2 and VEGF-A in the CIN 3 and cervical cancer". [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/313599.
Texto completo da fonteTexto em português e inglês
Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-23T06:30:30Z (GMT). No. of bitstreams: 1 Westin_MariaCristinadoAmaral_D.pdf: 3122088 bytes, checksum: 3d2afed3690cd3566bbb3fe26bb492a3 (MD5) Previous issue date: 2013
Resumo: Introdução: O carcinoma escamoso do colo uterino é precedido pela neoplasia intraepitelial cervical grau 3 (NIC 3). A invasão tumoral envolve a degradação da matriz extracelular e membrana basal do epitélio por enzimas proteolíticas denominadas metaloproteinases (MMPs). Os inibidores teciduais das metaloproteinases (TIMPs) também interferem no processo de invasão. Angiogênese é condição indispensável para a progressão tumoral. Objetivo: Analisar a expressão de MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2 e VEGF-A na NIC 3 e carcinoma do colo uterino. Sujeito e Métodos: Estudo do tipo comparativo observacional constituído de três grupos:- Grupo 1: 55 casos com diagnóstico de NIC 3, Grupo 2: 30 casos com NIC 3 e carcinoma associados e Grupo 3: 46 casos com carcinoma. A expressão protéica foi pesquisada separadamente nas células tumorais e estromais por reação imunoistoquímica. Para estabelecer a porcentagem de células imunopositivas utilizou-se software morfométrico. Análise Estatística: Aplicou-se o Teste T-pareado ou de Mann-Whitney ou Wilcoxon Signed Rank. Resultados: Em todos os grupos, a expressão tumoral de MMP-14 foi maior que a estromal. Inversamente, a expressão de TIMP-2 foi maior nas células estromais que nas tumorais, em cada grupo diagnóstico. A expressão de MMP-9 foi maior nas células estromais que nas tumorais, com exceção do componente invasor do Grupo 2. A expressão estromal de TIMP-1 foi maior que a tumoral no carcinoma e, ao contrário, sua expressão foi maior nas células tumorais da NIC 3. A expressão de VEGF-A foi maior apenas nas células tumorais da NIC 3. Comparando a expressão dos marcadores entre os grupos, foram encontradas as maiores diferenças entre grupos extremos, ou seja, entre NIC 3 e carcinoma. A expressão de MMP-2 nas células estromais foi maior no componente NIC 3 do Grupo 2 que no NIC 3 do Grupo 1. A expressão de VEGF-A nas células estromais do carcinoma foi maior que nas células estromais da NIC 3. Conclusões: Os resultados deste estudo sugerem que a expressão de TIMP-1 aumenta nas células do estroma e diminui nas células tumorais quando a NIC 3 progride para carcinoma invasor. MMP-9 e TIMP-2 tiveram expressão similar na NIC 3 e no carcinoma, o que limita inferências sobre seu papel na progressão neoplásica. O padrão imunoistoquímico da expressão das MMPs, TIMPs e VEGF-A na NIC 3 e no carcinoma invasivo, quando estas lesões estavam associadas, foi semelhante. A expressão do VEGF-A foi maior nas células tumorais do que nas estromais da NIC 3, porém quando esta lesão progride para carcinoma invasivo sua expressão aumenta nas células do estroma e não se altera nas tumorais. A expressão de MMP-14, MMP-2, TIMP-1 e VEGF-A aumentou com a gravidade da neoplasia
Abstract: Introduction: Squamous cell carcinoma of the cervix is preceded by cervical intraepithelial neoplasia grade 3 (CIN 3). Tumor invasion involves degradation of extracellular matrix and epithelium basement membrane by proteolytic enzymes called metalloproteinases (MMPs). Tissue inhibitors of metalloproteinases (TIMPs) are also involved in the invasion process. Angiogenesis is a prerequisite for tumor progression. Objective: To analyze the expression of MMP-2, MMP-9 and MMP-14, TIMP-1, TIMP-2 and VEGF-A in CIN 3 and invasive carcinoma. Subject and Methods: This comparative observational study was consists of three groups: Group 1: 55 cases diagnosed with CIN 3, Group 2: 30 cases with CIN 3 associated with invasive carcinoma and Group 3: 46 cases with invasive carcinoma. Protein expression was investigated separately in tumor and stromal cells by immunohistochemistry and evaluated by the percentage of cells positive for immunostaining using morphometric software. Statistical Analysis: Was performed applying paired t-test or Mann-Whitney or Wilcoxon Signed Rank. Results: In each diagnostic group, expression markers were significantly higher: MMP-14 in tumor cells, and TIMP-2 in stromal cells; also MMP-9 expression was significantly higher in stromal cells, except in invasive component of group 2, and TIMP-1 had significantly higher expression in stromal cells of invasive carcinoma and in tumor cells of CIN 3. VEGF-A expression was significantly higher only in tumor cells CIN 3. Comparing the expression of markers between groups, two by two, we find the greatest differences between the extreme groups, i.e. between invasive carcinoma and CIN 3. The expression of MMP-2 was significantly greater in the stromal component CIN 3 in group 2 than in CIN 3 only. The expression of VEGF-A was significantly higher in the group stromal cell carcinoma when compared to stromal cells CIN 3. Conclusions: The results of this study suggest that the expression of TIMP-1 increases in the stromal cells and decreases in tumor cells when CIN 3 progresses to invasive carcinoma. MMP-9 and TIMP-2 had similar expression in CIN 3 and invasive carcinoma, which limits inferences about its role in neoplastic progression. The immunohistochemical pattern of expression of MMPs, TIMPs and VEGF-A in CIN 3 and invasive carcinoma, as these lesions were associated, was similar. The expression of VEGF-A was higher in tumor cells than in stromal cells in CIN 3, but when the lesion progresses to invasive carcinoma its expression increases in the stromal cells and the tumor cells does not change. The expression of MMP-14, MMP-2, TIMP-1 and VEGF-A was increased with the severity of the neoplasia
Doutorado
Oncologia Ginecológica e Mamária
Doutora em Ciências da Saúde
Mazzone, Marco. "Role of intracellular transport, sorting and release of membrane type 1 matrix metalloproteinase (MT1-MMP) in tumor cell invasion and metastic dissemination". Thesis, Open University, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.422024.
Texto completo da fonteSolotskaya, Anna. "NEUTROPHIL PRODUCTS CONTROL THE EXPRESSION OF PROGESTERONE RECEPTORS AND MATRIX METALLOPROTEINASE-1 IN THE DECIDUAL AND MYOMETRIUM AND ARE POSSIBLE REGULATORS OF PREMATURE LABOR". VCU Scholars Compass, 2010. http://scholarscompass.vcu.edu/etd/2112.
Texto completo da fonteRuokolainen, H. (Henni). "The prognostic role of matrix metalloproteinase -2 and -9 (MMP-2, MMP-9) and their tissue inhibitors -1 and -2 (TIMP-1, TIMP-2) in head and neck squamous cell carcinoma". Doctoral thesis, University of Oulu, 2005. http://urn.fi/urn:isbn:9514279174.
Texto completo da fonteMiki, Takao. "The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase (MT1-MMP) and CD13/aminopeptidase N (APN), and modulates their endocytic pathways". Kyoto University, 2007. http://hdl.handle.net/2433/135757.
Texto completo da fonteMeschiari, César Arruda. "Concentrações de MMP-8, MMP-9, MPO, TIMP-1 e TIMP-2 na saliva e correlações com plasma". Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/17/17133/tde-12032012-110848/.
Texto completo da fonteMatrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases known to cleave components of the connective tissue in physiological and pathological processes. The regulation of MMP activities is done by the tissue inhibitors of metalloproteinases (TIMPs). Periodontal disease (PD) is a chronic inflammation with excessive activity of MMPs, which degrade the tooth supporting tissues. The saliva components are derived from the local blood supply, and this fluid may therefore reflect the plasma. So, the objectives of this study were: 1) to compare the levels of MMPs, TIMPs and MPO in stimulated whole saliva (SWS) and plasma of PD patients before (PB) and 3 months after (PT) the non-surgical periodontal treatment, and in healthy volunteers at baseline (CB) and 3 months after baseline (CT), and 2) to evaluate the correlations between the results found. Measurements of MMP-8, MMP-9, TIMP-1 and TIMP-2 were performed by ELISA. Gelatinolitic activity of MMP-9 forms were determined by zymography, and the MPO activity was determined by colorimetric assay. There was lower gelatinolitic activity, and lower concentrations of MMP-8 and TIMP-2 in SWS on PT group compared with PB group (p <0.05). MPO activity was higher in PB compared to CB (p <0.05). Statistically significant moderate correlations were observed in all associations between MMP-9 performed by ELISA in plasma and gelatinolitic activity bands of STE: MMP-9 molecular form of 92 kDa (r = 0,37, p = 0,0017), MMP-9 molecular form of 130 kDa (r = 0,35, p = 0,003), the sum of its gelatinase activity (130 +92 kDa) (r = 0,43, p = 0,0002), gelatinase of 180 kDa (r = 0,35, p = 0,003), and the sum of total gelatinase activity (180+130+92 kDa) (r = 0,37, p = 0,002). Circulating MMP-8 levels correlate with salivary gelatinase activity bands of 92 kDa (r = 0,30, p = 0,01) and the sum of gelatinase activity (130 +92 kDa) (r = 0,24, p = 0,04). In addition, a weak correlation between gelatinase activity of plasmatic 92 kDa MMP-9 and gelatinase of 180 kDa in SWS (r= 0,26 p = 0,03) was found, and a moderate correlation between plasmatic TIMP-2 and TIMP-2 of SWS (r = 0,32, p = 0,004). The results show that the gelatinase activity of SWS may reflect the concentrations of systemic inflammatory markers such as MMP-8 and MMP-9, also the concentration of TIMP-2 in the SWS may reflect the circulating concentration of TIMP-2. The evaluation of these results suggests that there is an attenuation of some inflammatory markers analyzed in the SWS and in plasma after treatment of PD. Furthermore, there are correlations between salivary and plasma levels in some of these markers. Because saliva sampling is less invasive, more studies about the correlations between these markers in these two fluids are necessary.
Seabra, Fl?vio Roberto Guerra. "An?lise imuno-histoqu?mica das metaloproteinases da matriz ( MMP-1,MMP-2 e MMP-9) na doen?a periodontal". Universidade Federal do Rio Grande do Norte, 2006. http://repositorio.ufrn.br:8080/jspui/handle/123456789/17147.
Texto completo da fonteThe tissular destruction found in periodontal diseases is caused mainly by components of the host that have its production stimulated by the products of the microorganisms present on the plaque. Matrix Metalloproteinases (MMPs), a class of enzymes involved both in physiologic and pathologic extracellular matrix degradation are considered the main responsible for the characteristic tissular loss in periodontal disease, and the understanding of how this happens can have a series of beneficial implications for prevention, diagnosis and treatment of this illness. The aim of this work was to study the immunohistochemical expression of MMP-1, MMP-2, and MMP-9 in fragments of gingival biopsies with clinical diagnose of periodontal disease. MMP-1 has expressed significantly more than the others MMPs in gingivitis both in the epithelium (p=0,0008) and connective tissue (p=0,0049). In periodontitis, both MMP-1 and MMP-9 has expressed significantly more than MMP-2 in the epithelium (p<0,0001) and in the connective tissue (p=0,0002). MMP-1 and MMP-9 presented more expression in periodontitis than in gingivitis but MMP-1 only in the connective tissue (p=0,03) and MMP-9 in the epithelium (p=0,003) and in the connective tissue (p=0,04). In conclusion, these results indicate that the MMP-1 presents high expression in every stages of the periodontal diseases, and increases its expression in the connective tissue when the gingivitis evolves to periodontitis. Therefore, it may have an important role in connective tissue degradation and bone loss observed in disease, since early, in gingivitis, until late stages, in periodontitis, of the periodontal disease. MMP-9 has expressed more in periodontitis than in gingivitis, both in epithelium and in connective tissue. It means that this enzyme may have some importance in the progression of gingivitis to periodontitis by acting in bone resorption observed in this desease
A destrui??o tecidual observada na doen?a periodontal ? causada, principalmente, por componentes do hospedeiro que t?m sua produ??o estimulada pelos produtos liberados pelas bact?rias. As Metaloproteinases da Matriz ou MMPs, enzimas relacionadas ? degrada??o de matriz extracelular em processos tanto fisiol?gicos quanto patol?gicos s?o consideradas as principais respons?veis pela perda tecidual caracter?stica da doen?a periodontal, e o entendimento de como isso ocorre pode ter uma s?rie de implica??es ben?ficas em rela??o ? preven??o, ao diagn?stico e ao tratamento desta doen?a. Neste trabalho foi estudada a express?o imuno-histoqu?mica da MMP-1, da MMP-2 e da MMP-9 em gengivas clinicamente diagnosticadas com doen?a periodontal. A MMP-1 teve express?o significativamente maior que as outras duas nos casos de gengivite tanto no epit?lio (p=0,0008) quanto no tecido conjuntivo (p=0,0049). Na periodontite, a MMP-1 e MMP-9 tiveram express?es significativamente maiores que a MMP-2 tanto no epit?lio (p<0,0001) quanto no conjuntivo (p=0,0002). A MMP-1 e MMP-9 mostraram maior express?o na periodontite que na gengivite sendo a MMP-1 apenas no tecido conjuntivo (p=0,03) e a MMP-9 no epit?lio (p=0,003) e no conjuntivo (p=0,04). Concluiu-se portanto que a MMP-1 apresenta forte express?o em todos os est?gios da doen?a peridontal, aumentando no tecido conjuntivo no caso de progress?o para periodontite, podendo portanto ter um papel crucial na degrada??o de tecido conjuntivo e perda ?ssea observada na doen?a desde os est?gios iniciais de gengivite at? a progress?o para periodontite. A MMP-9, ? expressa mais na periodontite que na gengivite, tanto no epit?lio quanto no conjuntivo significando que esta enzima pode ter import?ncia na progress?o da gengivite para a periodontite atuando na reabsor??o ?ssea observada na doen?a periodontal
Juliasse, Luiz Eduardo Rodrigues. "Estudo da express?o imuno-histoqu?mica das prote?nas MMP-9, MMP-13 e TIMP-1 em ameloblastomas e tumores odontog?nicos ceratocistos". Universidade Federal do Rio Grande do Norte, 2014. http://repositorio.ufrn.br:8080/jspui/handle/123456789/17136.
Texto completo da fonteConselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
Ameloblastomas and keratocystic odontogenic tumors (KOT) represent odontogenic lesions that, despite their benign nature, are distinguished by a distinct biological behavior, characterized by locally aggressive growth and recurrent episodes. The gnathic bone resorption caused by the growth of these lesions is a key to the expansion of the same, both being mediated by osteoclastic cells like enzymatic activity of various matrix metalloproteinases (MMPs) factor. The expression of stimulatory factors and inhibitors of bone resorption has been correlated with the development of these lesions, with emphasis to some MMPs such as collagenases and gelatinases and tissue inhibitors of metalloproteinases (TIMPs), among others. Based on the premise that stimulatory and inhibitory factors of osteolytic processes can be decisive for the growth rate of intraosseous odontogenic lesions, this experiment evaluated the immunoreactivity of MMP-9, -13 and TIMP-1 protein in the epithelium and mesenchyme of ameloblastoma and the KOT specimens, by a quantitative analysis of the immunoreactivity cells. Statistical analysis was performed using the Mann-Whitney and Wilcoxon tests with a significance level set at 5 %. Immunohistochemical expression of MMP-9, -13 and TIMP-1 was observed in 100% of cases both in the epithelium and in mesenchyme. The immunoreactivity in the epithelium of KOT and ameloblastomas revealed a predominance of score 3 for MMP-9 (p=0.382) and MMP-13 (p=0.069) and no statistically significance for TIMP-1, the latter being significantly higher immunoreactivity in ameloblastomas. In the mesenchyme, there was a higher score immunoreactivity of MMP-13 (p=0.031) in ameloblastomas in relation to KOT, whereas for MMP-9 and TIMP-1 no statistically significant difference (p=0.403 was observed, p=1.000). The calculation of the ratio of scores revealed expression of proteins in general, similarity of the lesions, a significant predominance of equal expression of TIMP-1 and MMP-9 was observed only in the epithelium of ameloblastoma. The marked immunostaining of MMP-9 , MMP-13 and TIMP-1 in epithelium and mesenchyme of the lesion indicate that these proteins involved in ECM remodeling required for tumor progression, however, specific differences in the expression of some of these proteins, are not sufficient to suggest differences in the biological behavior of ameloblastomas and KOTs
Os ameloblastomas e tumores odontog?nicos ceratoc?sticos (TOC) representam les?es odontog?nicas que, apesar de sua natureza benigna, se destacam por um comportamento biol?gico distinto, caracterizado pelo crescimento localmente agressivo e epis?dios recidivantes. A reabsor??o dos ossos gn?ticos provocada pelo crescimento dessas les?es constitui um fator determinante ? expans?o das mesmas, sendo mediada tanto por c?lulas osteocl?sticas como pela a??o enzim?tica de diversas metaloproteinases de matriz (MMPs). A express?o de fatores estimuladores e inibidores da reabsor??o ?ssea vem sendo correlacionada com o desenvolvimento destas les?es, merecendo destaque algumas MMPs como as colagenases e as gelatinases e os inibidores teciduais de metaloproteinases (TIMPs), dentre outros. Baseados na premissa de que fatores estimuladores e inibidores de processos osteol?ticos podem ser determinantes para o ritmo de crescimento de les?es odontog?nicas intra?sseas, o objetivo de estudo foi avaliar a imunoexpress?o das prote?nas MMP-9, -13 e TIMP-1 no epit?lio e mes?nquima de esp?cimes de ameloblastomas e TOC. A an?lise estat?stica foi realizada atrav?s dos testes de Mann-Whitney e Wilcoxon com n?vel de signific?ncia estabelecido em 5%. Atrav?s de uma an?lise quantitativa das c?lulas imunomarcadas, foi observada a express?o imuno-histoqu?mica das MMP-9, -13 e TIMP-1 em 100% dos casos, tanto no epit?lio quanto no mes?nquima tumoral. Mais de 76% das c?lulas epiteliais (escore 3) dos TOC e ameloblastomas apresentaram imunomarca??o para MMP-9 (p=0,382) e MMP-13 (p=0,069), sendo estatisticamente significativa para o TIMP-1 (p=0,003) nos ameloblastomas. No mes?nquima, observou-se maior escore de imunomarca??o da MMP-13 (p=0,031) nos ameloblastomas em rela??o aos TOC, enquanto para a MMP-9 e TIMP-1 n?o se observou diferen?a estatisticamente significativa (p=0,403; p=1,000). O c?lculo da raz?o entre os escores de express?o das prote?nas revelou, de uma maneira geral, similaridade entre as les?es, sendo observado predom?nio significante de igualdade de express?o do TIMP-1 e da MMP-9 apenas no epit?lio dos ameloblastomas. A imunoexpress?o marcante das MMP-9, MMP-13 e TIMP-1 no epit?lio e mes?nquima das les?es estudadas indica que estas prote?nas participam na remodela??o da MEC necess?ria ? progress?o tumoral, no entanto, as diferen?as pontuais observadas na express?o de algumas destas prote?nas, n?o s?o suficientes para sugerir diferen?as no comportamento biol?gico dos ameloblastomas e dos TOCs
Butt, Louise. "Structure-function relationships in matrix metalloproteinase-1". Thesis, University of Portsmouth, 2013. https://researchportal.port.ac.uk/portal/en/theses/structurefunction-relationships-in-matrix-metalloproteinase1(2b3318eb-8f07-48ab-8b00-b77a1e069d71).html.
Texto completo da fonteCox, Kathryn Elizabeth. "Matrix metalloproteinase-3 in uterus and endometriosis". free to MU campus, to others for purchase, 2001. http://wwwlib.umi.com/cr/mo/fullcit?p3012963.
Texto completo da fonteJustulin, Junior Luis Antonio. "Efeitos da doxazosina e da combinação doxasina mais finasterida sobre a interação parenquina-estroma na prostata de rato : proliferação, morte celular, atividade das MMPs-2 e 9 e expressão genica dos TIMPs 1 e 2". [s.n.], 2008. http://repositorio.unicamp.br/jspui/handle/REPOSIP/317949.
Texto completo da fonteTese (doutorado) - Universidade Estadual de Campinas, Insituto de Biologia
Made available in DSpace on 2018-08-13T04:30:25Z (GMT). No. of bitstreams: 1 JustulinJunior_LuisAntonio_D.pdf: 17091914 bytes, checksum: 15d52dabcde65a4f842895fd71f92ccd (MD5) Previous issue date: 2008
Resumo: Finasterida (Fin), um inibidor da enzima 5a-redutase do tipo II e a Doxazosina (Dox), um inibidor do receptor a1-adrenérgico, tem sido amplamente utilizados no tratamento dos sintomas da Hiperplasia Prostática Benigna (HPB). Recentemente, dados clínicos demonstraram que a combinação destas drogas foi mais efetiva em prevenir o desenvolvimento de retenção urinária aguda. Além disso, tem sido demonstrado que tanto as drogas isoladas, como em associação também podem ser utilizadas na prevenção e tratamento do câncer de próstata, devido ao seu potencial de induzir apoptose em células epiteliais normais e tumorais. Apesar disso, pouco se conhece sobre os efeitos da Fin e da Dox administradas isoladas ou em associação sobre a morfofisiologia prostática, incluindo proliferação, morte celular, e indução de remodelação da matriz extracelular pelas metaloproteinases de matriz. Ratos wistar machos adultos (13 semanas) foram tratados com Dox (25mg/kg/dia) ou com a combinação de Fin+Dox (25mg/kg/dia). Após a eutanásia, os lobos prostáticos (ventral, dorsolateral e anterior) foram retirados, pesados e imersos em fixador para análises morfológicas ou congelados em nitrogênio líquido para posterior análises bioquímicas. Os resultados morfológicos e estereológicos demonstraram que o tratamento com a Dox isoladamente por 3 dias resultou em aumento do peso da próstata ventral, com acúmulo de secreção na luz glandular. Os pesos absoluto e relativo das próstatas dorsolateral e anterior não sofreram alteração neste período de tratamento. Entretanto, após 30 dias de tratamento, observou-se uma redução de aproximadamente 20% nos pesos absoluto e relativo de todos os lobos prostáticos e um aumento do volume glandular ocupado pelo colágeno no estroma nos três lobos prostáticos. O tratamento com doxazosina também reduziu o índice de proliferação celular e aumentou o índice apoptótico em todos os períodos analisados. A próstata ventral de ratos tratados com a combinação de Fin+Dox apresentou perda de peso após 30 dias de tratamento. Nos dois períodos de tratamento ocorreu diminuição do índice de proliferação celular, aumento de apoptose e do volume estromal de colágeno, mais evidentes quando comparados ao tratamento com as drogas isoladas. O tratamento combinado também provocou aumento da imunomarcação para o TGF-ß1 demonstrado por imunohistoquímica, principalmente no epitélio. A expressão dos RNAms para MMP-2, TIMPs-1 and - 2 dimunuiu após 30 dias de tratamento, enquanto o RNAm para a MMP-9 não foi detectado em nenhum grupo experimental. O tratamento com Fin+Dox por 30 dias promoveu uma diminuição na atividade gelatinolítica da MMP-2 e um aumento na atividade da MMP-9. Em conjunto, os resultados deste estudo demonstram que tanto o tratamento com doxazosina quanto o tratamento combinado de Fin+Dox induzem grandes alterações glandulares que levam a atrofia prostática, sendo ainda mais significativa com o tratamento combinado, possivelmente pela ação complementar destas duas drogas sobre o parênquima e o estroma glandulares. Nesta atrofia, a MMP-9 e o TGF-ß 1parecem desempenhar um papel importante. Desta forma, nossos resultados auxiliam o entendimento dos dados clínicos, demonstrando que a combinação dos dois fármacos pode ser mais eficaz no tratamento da HPB.
Abstract: Finasteride (Fin), an inhibitor of type II 5-a reductase, and Doxazosin (Dox), an a1- adrenergic blocker, have been widely used in treatment of Benign Prostate Hyperplasia (BPH) symptoms. Recently, clinical data have demonstrated that the combined therapy with Fin+Dox reduced the long-term risk of acute urinary retention and the need for invasive therapies than either drug alone. Moreover, both drugs, alone or in combination have been suggested to be effective in the treatment of prostate cancer by inducing apoptosis in normal and tumoral cells. However, little is known about the effects of these drugs administrated alone or their combination on prostate tissue morphohysiology, including prostate morphology, cell proliferation, apoptosis and matrix metalloproteinases activities. Male adult Wistar rats (13 weeks old) were treated with doxazosin (25mg/kg/day) or with finasteride (25mg/kg/day) or with the combination of both drugs. The ventral (VP), dorsolateral (DLP) and anterior prostate (AP) were excised and processed for histochemical, morphometric and biochemical analysis. The results of morphological and stereological analyses demonstrate that Dox treatment for 3 day resulted in an increased in ventral prostate absolute and relative weight with secretion accumulation. The weight of dorsolateral and anterior prostate did not change in this period of treatment. However, after 30 days, the prostate exhibited an absolute and relative weight reduction of about 20% and an increase in collagen volume fraction in the stromal space in the three prostatic lobes. Dox also reduced epithelial cell proliferation and increased apoptosis in the three prostatic lobes in all periods of tretament. Rat VP treated with Fin+Dox also presented a reduction in absolute and relative weight, decrease in epithelial cell proliferation, increase in apoptosis and collagen volume fraction in the stroma in all periods analyzed, more than Dox alone. Fin+Dox treatment also increased the TGF-ß 1 immunoreaction in the epithelium and in the stroma of VP. The mRNA for MMP-2, TIMPs-1 and - 2 expression after 30 days of treatment were decreased. The mRNA for MMP-9 was not detected in any groups analyzed. Fin+Dox treatment for 30 days promoted a decrease in gelatinolitic activity of MMP-2 and an increase in MMP-9. Take together, these results demonstrated that both Dox alone or in combination with Fin induced changes in glandular histoarchitecture, leading to a prostate atrophy, being the combined treatment more effective in inducing glandular atrophy, possibly to the complementary action of the Fin and Dox on prostate parenchyma and stroma, respectively. In this process, the MMP-9 and TGF-ß1 appear to participate effectively. Our results contribute to a better understanding of the clinical data, demonstrating that the combined treatment can be more effective in the BPH treatment.
Doutorado
Biologia Celular
Doutor em Biologia Celular e Estrutural
Pullen, Nicholas. "THE INFLUENCES OF MATRIX METALLOPROTEINASE-1 EXPRESSION ON GLIOBLASTOMA PATHOLOGY". VCU Scholars Compass, 2010. http://scholarscompass.vcu.edu/etd/2037.
Texto completo da fonteKuvaja, P. (Paula). "The prognostic role of matrix metalloproteinases MMP-2 and -9 and their tissue inhibitors TIMP-1 and -2 in primary breast carcinoma". Doctoral thesis, University of Oulu, 2007. http://urn.fi/urn:isbn:9789514285998.
Texto completo da fonteLehti, Kaisa I. "Membrane-type-1 matrix metalloproteinase in pericellular proteolysis and cell migration". Helsinki : University of Helsinki, 2002. http://ethesis.helsinki.fi/julkaisut/laa/haart/vk/lehti/.
Texto completo da fonteJavaid, Mohammad. "Platelet factor 4 upregulates matrix metalloproteinase-1 production in gingival fibroblasts". Thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/60244.
Texto completo da fonteDentistry, Faculty of
Graduate
Labbene, Azza [Verfasser], e Nikolas [Akademischer Betreuer] Mirow. "Rolle der Matrix-Metalloproteinasen bei der Mitralklappeninsuffizienz: Assoziation zwischen der Expression von MMP-1, MMP-9, TIMP-1 und TIMP-2, dem Mitralinsuffizienzgrad und der Ätiologie / Azza Labbene ; Betreuer: Nikolas Mirow". Marburg : Philipps-Universität Marburg, 2019. http://d-nb.info/1199537500/34.
Texto completo da fonteNaveed, Shams-un-nisa. "Matrix metalloproteinase-1 mediated extra-cellular matrix remodelling contributes to airway smooth muscle growth and asthma severity". Thesis, University of Nottingham, 2018. http://eprints.nottingham.ac.uk/50577/.
Texto completo da fonteFalkenberg, Sonja. "Expression der Matrix-Metalloproteinasen MMP-2, -7, -9 und -13 und ihrer Inhibitoren TIMP-1, -2 und -3 in Plattenepithelkarzinomen des oberen Aerodigestivtraktes". [S.l.] : [s.n.], 2004. http://archiv.ub.uni-marburg.de/diss/z2004/0679/.
Texto completo da fonteHussain, Shaista. "Signalling pathways implicated in the growth factor and cytokine mediated up regulation of gelantinase B, collagenase 1 and stromelysin-1 in rabbit aortic smooth muscle cells in vitro". Thesis, University of Bristol, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.340275.
Texto completo da fonteHartland, Stephen. "Mechanistic analyses of transforming growth factor-Î’-mediated repression of matrix metalloproteinase-1". Thesis, University of Newcastle Upon Tyne, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.430407.
Texto completo da fonteDurkan, Garrett Christopher. "Matrix metalloproteinase-1 and -9 and tissue inhibitor of metalloproteinase-1 in bladder cancer : pathophysiological significance and relationship to epidermal growth factor receptor expression". Thesis, University of Newcastle Upon Tyne, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.369832.
Texto completo da fonteFischoeder, Arne [Verfasser]. "Regulation von Matrix Metalloproteinase-9 durch Insulin in humanen THP-1 Monozyten / Arne Fischoeder". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2009. http://d-nb.info/1023784432/34.
Texto completo da fonteShimizu, Makoto. "Hyaluronan Inhibits Matrix Metalloproteinase-1 Production by Rheumatoid Synovial Fibroblasts Stimulated by Proinflammatory Cytokines". Kyoto University, 2004. http://hdl.handle.net/2433/147561.
Texto completo da fonteFreitas, Val?ria Souza. "Estudo da express?o imuno-histoqu?mica das MMPs -2, -7, -9 e -26 e TIMPs -1 e -2 em adenomas pleom?rficos e carcinomas aden?ides c?sticos de gl?ndulas salivares menores". Universidade Federal do Rio Grande do Norte, 2011. http://repositorio.ufrn.br:8080/jspui/handle/123456789/17149.
Texto completo da fonteConselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
The balance between the expression of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) has been related to various physiological and pathological processes, including salivary gland morphogenesis and tumor invasion and metastasis processes. Pleomorphic adenoma (PA) and adenoid cystic carcinoma (ACC) respectively represent benign and malignant neoplasias of salivary glands. Although they share the same cell origin, they present distinct biological behavior. The aim of this study was to compare the immunohistochemical expression of MMPs -2, -7, -9 and -26, and of TIMPs -1 and -2, in cases of PA and ACC of minor salivary glands. Twenty cases of PA and twenty cases of ACC were assessed according to the presence, intensity and location of MMPs and TIMPs in the tumor parenchyma. Most of the PAs and ACCs presented a high expression of MMP -2, -7, -9 and -26 and of TIMP -1 and -2, predominantly located in tumor cells. There was no significant difference in the expression of MMPs -2 (p=0.359), -7 (p=0.081) and -26 (p=0.553), as well as of TIMPs -1 (p=0.657) and -2 (p=0.248), between the parenchyma of PAs and ACCs. However, MMP-9 showed a significant difference of expression between the two tumors, with the ACC showing more intense marking for this gelatinase (p=0.041). The strong expression of MMP-9 observed in the parenchyma suggests that this gelatinase may play an important role in the biological behavior of these tumors. On the other hand, although there was no significant difference between the marking of MMP -2, 7 and 26 in the studied tumors, the data, when analyzed as a whole, suggest that these proteases may take part in the process of tissue remodeling in both tumors, but do not present a direct relation with the pattern of aggressiveness of ACC. Nonetheless, matrilisins may indirectly influence the behavior of this tumor due to their capacity of activating MMP-9, strongly expressed in the parenchyma of ACC
O balan?o entre a express?o das metaloproteinases da matriz (MMPs) e seus inibidores teciduais (TIMPs) tem sido relacionado a v?rios processos fisiol?gicos e patol?gicos, incluindo a morfog?nese de gl?ndulas salivares e os processos de invas?o e met?stase tumoral. O adenoma pleom?rfico (AP) e o carcinoma aden?ide c?stico (CAC) representam, respectivamente, neoplasias benignas e malignas de gl?ndulas salivares que, embora compartilhem a mesma origem celular, apresentam comportamentos biol?gicos distintos. O prop?sito deste estudo foi comparar a express?o imuno-histoqu?mica das MMPs -2, -7, -9 e - 26 e dos TIMPs -1 e -2 em casos de AP e CAC de gl?ndulas salivares menores. Vinte casos de AP e vinte casos de CAC foram avaliados quanto ? presen?a, intensidade e localiza??o das MMPs e TIMPs no par?nquima tumoral. A maioria dos APs e CACs apresentaram alta express?o das MMPs e dos TIMPs, predominantemente localizada nas c?lulas tumorais. N?o houve diferen?a estatisticamente significativa na express?o das MMPs -2 (p=0,359), -7 (p=0,081) e -26 (p=0,553), bem como dos TIMPs -1 (p=0,657) e -2 (p=0,248), entre o par?nquima dos APs e CACs. A MMP-9 demonstrou uma diferen?a significativa de express?o entre os dois tumores, apresentando o CAC uma marca??o mais intensa para esta gelatinase (p=0,041). A forte express?o da MMP-9 observada no par?nquima dos CACs sugere que esta gelatinase possa desempenhar um papel importante no comportamento biol?gico destes tumores. Por outro lado, apesar de n?o ocorrer uma diferen?a significativa entre as m?dias das MMPs -2, 7 e 26 nos tumores estudados, os dados quando analisados em conjunto sugerem que estas proteases podem estar participando de processos de remodela??o tecidual em ambos os tumores, mas n?o apresentam uma rela??o direta com o padr?o de agressividade do CAC. Entretanto, as matrilisinas poderiam influenciar indiretamente o comportamento deste tumor devido a sua capacidade de ativar a MMP-9, fortemente expressa no par?nquima destes tumores
Hovell, Christopher John. "Membrane-type 1 matrix metalloproteinase expression by hepatic stellate cells : its role in liver fibrosis". Thesis, University of Southampton, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.322017.
Texto completo da fonteMedeiros, Mildred Ferreira. "Hanseníase neural, aspectos diagnósticos da forma neural pura e mecanismos imunopatogênicos da lesão do nervo na doença. Participação de quimiocinas CCL2 e CXCL10 e metaloproteinases 2 e 9". Universidade do Estado do Rio de Janeiro, 2014. http://www.bdtd.uerj.br/tde_busca/arquivo.php?codArquivo=7356.
Texto completo da fonteO diagnóstico da hanseníase neural pura baseia-se em dados clínicos e laboratoriais do paciente, incluindo a histopatologia de espécimes de biópsia de nervo e detecção de DNA de Mycobacterium leprae (M. leprae) pelo PCR. Como o exame histopatológico e a técnica PCR podem não ser suficientes para confirmar o diagnóstico, a imunomarcação de lipoarabinomanana (LAM) e/ou Glicolipídio fenólico 1 (PGL1) - componentes de parede celular de M. leprae foi utilizada na primeira etapa deste estudo, na tentativa de detectar qualquer presença vestigial do M. leprae em amostras de nervo sem bacilos. Além disso, sabe-se que a lesão do nervo na hanseníase pode diretamente ser induzida pelo M. leprae nos estágios iniciais da infecção, no entanto, os mecanismos imunomediados adicionam severidade ao comprometimento da função neural em períodos sintomáticos da doença. Este estudo investigou também a expressão imuno-histoquímica de marcadores envolvidos nos mecanismos de patogenicidade do dano ao nervo na hanseníase. Os imunomarcadores selecionados foram: quimiocinas CXCL10, CCL2, CD3, CD4, CD8, CD45RA, CD45RO, CD68, HLA-DR, e metaloproteinases 2 e 9. O estudo foi desenvolvido em espécimes de biópsias congeladas de nervo coletados de pacientes com HNP (n=23 / 6 BAAR+ e 17 BAAR - PCR +) e pacientes diagnosticados com outras neuropatias (n=5) utilizados como controle. Todas as amostras foram criosseccionadas e submetidas à imunoperoxidase. Os resultados iniciais demonstraram que as 6 amostras de nervos BAAR+ são LAM+/PGL1+. Já entre as 17 amostras de nervos BAAR-, 8 são LAM+ e/ou PGL1+. Nas 17 amostras de nervos BAAR-PCR+, apenas 7 tiveram resultados LAM+ e/ou PGL1+. A detecção de imunorreatividade para LAM e PGL1 nas amostras de nervo do grupo HNP contribuiu para a maior eficiência diagnóstica na ausência recursos a diagnósticos moleculares. Os resultados da segunda parte deste estudo mostraram que foram encontradas imunoreatividade para CXCL10, CCL2, MMP2 e MMP9 nos nervos da hanseníase, mas não em amostras de nervos com outras neuropatias. Além disso, essa imunomarcação foi encontrada predominantemente em células de Schwann e em macrófagos da população celular inflamatória nos nervos HNP. Os outros marcadores de ativação imunológica foram encontrados em leucócitos (linfócitos T e macrófagos) do infiltrado inflamatório encontrados nos nervos. A expressão de todos os marcadores, exceto CXCL10, apresentou associação com a fibrose, no entanto, apenas a CCL2, independentemente dos outros imunomarcadores, estava associada a esse excessivo depósito de matriz extracelular. Nenhuma diferença na frequência da imunomarcação foi detectada entre os subgrupos BAAR+ e BAAR-, exceção feita apenas às células CD68+ e HLA-DR+, que apresentaram discreta diferença entre os grupos BAAR + e BAAR- com granuloma epitelioide. A expressão de MMP9 associada com fibrose é consistente com os resultados anteriores do grupo de pesquisa. Estes resultados indicam que as quimiocinas CCL2 e CXCL10 não são determinantes para o estabelecimento das lesões com ou sem bacilos nos em nervo em estágios avançados da doença, entretanto, a CCL2 está associada com o recrutamento de macrófagos e com o desenvolvimento da fibrose do nervo na lesão neural da hanseníase.
The diagnosis of pure neural leprosy (PNL) is based on clinical and laboratory data, including the histopathology of nerve biopsy specimens and detection of M. leprae DNA by polymerase chain reaction (PCR). Given that histopathological examination and PCR methods may not be sufficient to confirm diagnosis, immunolabeling of lipoarabinomanan (LAM) and/or phenolic glycolipid 1 (PGL1) M. leprae wall components were utilized in the first step of this investigation in an attempt to detect any vestigial presence of M. leprae in AFB- nerve samples. Furthermore, its well known that nerve damage in leprosy can be directly induced by Mycobacterium leprae in the early stages of infection; however, immunomediated mechanisms add gravity to the impairment of neural function in symptomatic periods of the disease. Therefore, this study also investigated the immunohistochemical expression of immunomarkers involved in the pathogenic mechanisms of leprosy nerve damage. These markers selected were CXCL10, CCL2 chemokines and CD3, CD4, CD8, CD45RA, CD45RO, CD68, HLA-DR, metalloproteinases 2 and 9 in nerve biopsy specimens collected from leprosy (23) and nonleprosy patients (5) suffering peripheral neuropathy. Twenty-three PNL nerve samples (6 AFB+ and 17 AFB-PCR+) were cryosectioned and submitted to LAM and PGL1 immunohistochemical staining by immunoperoxidase; 5 nonleprosy nerve samples were used as controls. The 6 AFB-positive samples showed LAM/PGL1 immunoreactivity. Among the 17 AFB- samples, only 8 revealed LAM and/or PGL1 immunoreactivity. In 17 AFB-PCR+ patients, just 7 had LAM and/or PGL1-positive nerve results. In the PNL cases, the detection of immunolabeled LAM and PGL1 in the nerve samples would have contributed to enhanced diagnostic efficiency in the absence of molecular diagnostic facilities. The results of the second part of this study showed that CXCL10-, CCL2-, MMP2- and MMP9-immunoreactivities were found in the leprosy nerves but not in nonleprosy samples. Immunolabeling was predominantly found in recruited macrophages and Schwann cells composing the inflammatory cellular population in the leprosy-affected nerves. The immunohistochemical expression of all the markers, but CXCL10, was associated with fibrosis; however, only CCL2 was, independently from the other markers, associated with this excessive deposit of extracellular matrix. No difference in the frequency of the immunolabeling was detected between the AFB+ and AFB- leprosy subgroups of nerves, exception made to some statistical tendency to difference in regard to CD68+ and HLA-DR+ cells in the AFB- nerves exhibiting epithelioid granuloma. MMP9 expression associated with fibrosis is consistent with previous results of this research group. The findings conveys the idea that CCL2 and CXCL10 chemokines at least in advanced stages of leprosy nerve lesions are not determinant for the establishment of AFB+ or AFB- leprosy lesions, however, CCL2 is associated with macrophage recruitment and fibrosis.
Koch, Sabine. "Die Expression und Aktivität von Matrix-Metalloproteinase-1 wird durch Stickstoffmonoxid, reduzierte Thiole und Zytokine reguliert". [S.l.] : [s.n.], 2006. http://deposit.ddb.de/cgi-bin/dokserv?idn=983272174.
Texto completo da fonteMcCready, Jessica. "The Influence of a Single Nucleotide Polymorphism In The Matrix Metalloproteinase-1 Promoter on Glioma Biology". VCU Scholars Compass, 2006. http://scholarscompass.vcu.edu/etd/1123.
Texto completo da fontePacheco, Fernández Natalia María [Verfasser], e Reinhard [Akademischer Betreuer] Fässler. "Nucleobindin-1 modulates extracellular matrix remodeling by promoting intra-Golgi trafficking of matrix metalloproteinase 2 / Natalia María Pacheco Fernández ; Betreuer: Reinhard Fässler". München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2020. http://d-nb.info/1215499892/34.
Texto completo da fonteProthero, Joanna. "Matrix metalloproteinase-3 (stromelysin-1) gene promoter polymorphism in relation to predisposition to inflammatory bowel disease (IBD)". Thesis, University of Southampton, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436934.
Texto completo da fonteRauvala, M. (Marita). "Matrix metalloproteinases -2 and -9 and tissue inhibitors of metalloproteinases -1 and -2 in gynaecological cancers". Doctoral thesis, University of Oulu, 2006. http://urn.fi/urn:isbn:951428187X.
Texto completo da fontePradhan-Palikhe, P. (Pratikshya). "Matrix metalloproteinase-8 as a diagnostic tool for the inflammatory and malignant diseases". Doctoral thesis, Oulun yliopisto, 2011. http://urn.fi/urn:isbn:9789514295096.
Texto completo da fonteTiivistelmä Matriksin metalloproteinaasit (MMP:t) ovat sinkkiriippuvaisia endopeptidaaseja, jotka kuuluvat laajaan proteiineja pilkkovaan proteolyyttiseen entsyymi perheeseen. MMP:ien tehtävä on pilkkoa ja uudelleen muokata soluväliaineen proteiineja kasvun, elinten kehityksen ja kudosten uusiutumisen aikana, mutta MMP:t toimivat aktiivisesti myös patologisissa prosesseissa, kuten tulehdustiloissa ja syövissä. Syövissä MMP:en vaikutus voi johtaa ei-toivottuun kudostuhoon. Yksi laajimmin tutkituista MMP-ryhmän entsyymeistä on MMP-8, jonka alunpitäen ajateltiin ilmenevän vain neutrofiileissä. Nykytietämyksen mukaan MMP-8:aa ilmentyy myös mm. makrofaageissa, plasmasoluissa, T-soluissa, endoteelisoluissa, sileälihassoluissa, suun limakalvon epiteelisoluissa ja fibroplasteissa. MMP-8:aa on aikaisemmin tutkittu erityisesti tulehdustiloissa ja pahanlaatuisissa kasvaimissa. Korkean MMP-8 seerumipitoisuuden on havaittu liittyvän valtimokovettumatautiin ja huonoon ennusteeseen sydän- ja verisuonisairauksissa, kun taas kohonnut MMP-8:n pitoisuus plasmassa suojaa imusolmuke-etäpesäkkeiltä. Tiedetään, että tietyt muutokset MMP-8:n geenissä voivat muuttaa sen promoottoriaktiviteettia ja täten säädellä geenin ilmentymistä. MMP-8:n geenimuutokset vaikuttanevat raskaudenkulkuun sekä keuhko- ja rintasyövän ennusteeseen. Tutkimushypoteesimme mukaan MMP-8:n seerumipitoisuudet riippuvat vaihtelusta MMP-8:aa koodaavassa geenissä ja niitä voidaan pitää uusina riskinarvioinnin merkkiaineina tautitiloissa. Tavoitteenamme oli osoittaa yleisesti MMP:ien ja erityisesti MMP-8:n sekä näiden proteinaasien säätelytekijöiden merkitys tietyissä tulehdustiloissa ja maligniteeteissa, kuten sepelvaltimotaudissa ja pään ja kaulan alueen syövissä. Havaitsimme, että korkea MMP-8 seerumipitoisuus ja alhainen myeloperoksidaasitaso yhdistyvät vahvasti valtimotautiriskiin. Lisäksi osoitimme, että tietty MMP-8:n geenimuunnos on suojaava tekijä valtimotaudille ja että MMP-8:n seerumikonsentraatio on siitä riippuvainen terveillä tutkituilla. Tämän lisäksi todensimme, että MMP:n kudosestäjän (tissue inhibitor of matrix metalloproteinases, TIMP-1) plasmapitoisuus liittyy pään ja kaulan alueen levyepiteelisyöpää sairastavien potilaiden eloonjääntiin ja että TIMP-1:n genotyyppi liittyy sen plasmapitoisuuteen ainoastaan naisilla. Tulostemme mukaan seerumin MMP-8-pitoisuutta voidaan pitää hyvänä riskinarviointivälineenä verisuonitaudeissa sekä TIMP-1-pitoisuutta vastaavasti pään ja kaulan alueen levyepiteelisyövissä. Saadut tulokset tukevat olettamustamme, jonka mukaan MMP-8 on tärkeä tautimarkkeri. Tämä on lisännyt kiinnostusta selvittää MMP:ien merkitystä laajemmin muissa tulehdustiloissa ja syövissä. Jos tulokset saadaan toistetuksi laajemmassa tutkimusaineistossa, seerumin MMP-8:sta voidaan kehittää kliinisten ja analyyttisten laboratorioiden käyttöön sopiva diagnostinen menetelmä
Walia, Baljit S. "Matrix metalloproteinase activation in heart failure due to volume-overloa and the effect of AT¦1 receptor blockade". Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp01/MQ45160.pdf.
Texto completo da fonteYoshida, Masahiro. "Prostaglandin F2α, cytokines, and cyclic mechanical stretch augment matrix metalloproteinase-1 secretion from cultured human uterine cervical fibroblast cells". Kyoto University, 2004. http://hdl.handle.net/2433/147549.
Texto completo da fonte